Skip to content
DIAFIR logo

DIAFIR Alternatives & Competitors

12 companies similar to DIAFIR

Companies similar to DIAFIR

Apollon logo — alternative to DIAFIR

Apollon

The wearable that reads your glucose

Genomtec SA logo — alternative to DIAFIR

Genomtec SA

Molecular diagnosis everywhere, at the right time and for the right price.

Humedics GmbH logo — alternative to DIAFIR

Humedics GmbH

Quantifying functional liver capacity

WallabyPhenox logo — alternative to DIAFIR

WallabyPhenox

Leading Innovator in Interventional Neuroradiology

Rival Readout

Competing with DIAFIR? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Prestodiag logo — alternative to DIAFIR

Prestodiag

Pioneering rapid bacteria detection through advanced optics for swift, accurate results ac...

BD logo — alternative to DIAFIR

BD

BD is a global medical technology company that is advancing the world of health™.

Grifols logo — alternative to DIAFIR

Grifols

Develops, produces and provides innovative healthcare services and solutions in more than...

Lupin Pharmaceuticals logo — alternative to DIAFIR

Lupin Pharmaceuticals

There is only one reason why we exist — to treat diseases, to heal and enrich human life.

Elmaslar İmalat Tıbbi Cih. İnş. A.Ş. logo — alternative to DIAFIR

Elmaslar İmalat Tıbbi Cih. İnş. A.Ş.

Hayat sağlık ile başlar, sevdiklerinizle devam eder...

Entia logo — alternative to DIAFIR

Entia

Unlocking the full potential of cancer therapy with at-home blood monitoring

Abbott logo — alternative to DIAFIR

Abbott

Life-changing health technologies in the area of diagnostics, medical devices, nutritional...

Miracor Medical SA logo — alternative to DIAFIR

Miracor Medical SA

Miracor develops the PiCSO Impulse System to improve coronary microcirculation & reduce in...

About DIAFIR

DIAFIR, founded in 2011, is a French innovator at the intersection of Biotechnology, Manufacturing, and Medical Devices. The company specializes in developing rapid, in situ biological analytical tools leveraging proprietary infra-red fiber sensor technology. These groundbreaking systems have significant applications i...

Services

In vitro diagnostic device development, Spectroscopic analysis technology, Diagnostic testing for liver diseases, Synovial fluid infection risk assessment

Target Customers

Healthcare providers, Medical laboratories, Clinicians specializing in liver diseases, Veterinary diagnostics

Business keywords

Biological Analytical Tools, In Situ, Infra Red Fiber Sensor Technology, POC Medical Diagnostic, Food Analysis, Chemical Reaction Monitoring, Chronic Liver Disease Detection, Infection Detection, Tumor Detection, Fast Analysis, Diagnostic Technology, Medical Equipment

Frequently Asked Questions

Companies similar to DIAFIR include Apollon, Genomtec SA, Humedics GmbH, WallabyPhenox, Prestodiag. They work in Biotechnology and Medical Devices and share DIAFIR's focus on infection detection and diagnostic technology.
Bounce Watch lists 12 companies that share DIAFIR's industries and are closest to it in business tags, services, target customers, business model and size.
DIAFIR, founded in 2011, is a French innovator at the intersection of Biotechnology, Manufacturing, and Medical Devices. The company specializes in developing rapid, in situ biological analytical tools leveraging proprietary infra-red fiber sensor technology. These groundbreaking systems have significant applications i...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around DIAFIR: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at DIAFIR on 16 Sep 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Sep 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout